Cerdulatinib
10mM in DMSO
- Product Code: 157736
CAS:
1198300-79-6
| Molecular Weight: | 445.54 g./mol | Molecular Formula: | C₂₀H₂₇N₇O₃S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Cerdulatinib is primarily used in the research and development of treatments for hematologic malignancies, particularly B-cell lymphomas and leukemias. It functions as a dual inhibitor of JAK (Janus kinase) and SYK (spleen tyrosine kinase), two signaling proteins involved in immune cell activation and cancer cell proliferation. By blocking these pathways, cerdulatinib helps suppress abnormal immune signaling and tumor growth in certain blood cancers.
It has shown promise in preclinical and clinical studies for patients with relapsed or refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). Its dual inhibition mechanism offers a targeted approach that may overcome resistance seen with single-pathway inhibitors.
Cerdulatinib is also being investigated for use in autoimmune and inflammatory conditions due to its modulation of immune signaling pathways, though its primary focus remains in oncology research.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 1ml | 10-20 days | ฿6,500.00 |
+
-
|
Cerdulatinib
Cerdulatinib is primarily used in the research and development of treatments for hematologic malignancies, particularly B-cell lymphomas and leukemias. It functions as a dual inhibitor of JAK (Janus kinase) and SYK (spleen tyrosine kinase), two signaling proteins involved in immune cell activation and cancer cell proliferation. By blocking these pathways, cerdulatinib helps suppress abnormal immune signaling and tumor growth in certain blood cancers.
It has shown promise in preclinical and clinical studies for patients with relapsed or refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). Its dual inhibition mechanism offers a targeted approach that may overcome resistance seen with single-pathway inhibitors.
Cerdulatinib is also being investigated for use in autoimmune and inflammatory conditions due to its modulation of immune signaling pathways, though its primary focus remains in oncology research.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :